enrollment

January 14, 2019

Burkitt’s Lymphoma/Leukemia Patients Being Recruited for CPI-613 Phase 2 Trial

News

Rafael Pharmaceuticals is currently enrolling patients with relapsed or refractory Burkitt’s lymphoma/leukemia in a Phase 2 trial to assess the potential of its lead candidate CPI-613. The study (NCT03793140) is ... Read more

March 13, 2018March 13, 2018

Fighting Cancer, Accessing Best Treatment Are Why Patients Enroll in Phase 1 Trials, Study Finds

News

The top reasons why patients enroll in Phase 1 clinical trials are “fighting my cancer as much as possible” and “accessing the best treatment,” according to a study presented at ... Read more